SA Editor Douglas W. House
Healthcare, Biotech, special situations, event-driven, growth

Harvard Bioscience Bulls Need A Lot Of HART

A couple of months ago, I read an SA article about Harvard Bioscience (NASDAQ:HBIO) that posited there would be a significant upside move in price related to its spin-off of Harvard Apparatus Regenerative Technology (HART). The basis for the bullish thesis rested on the expectation that the market would respond enthusiastically to a new solo player in regenerative medicine. The author's view seemed reasonable in light of the bullish reception Organovo (NYSEMKT:ONVO) received when it up-listed on July 9.

I was already aware of HART because it was on deck to price its shares for an IPO back in the spring, but pulled back. It formally withdrew its S-1 on May 1, deciding instead to pursue...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details